Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential
Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential